Smith & Nephew plc (LON:SN - Get Free Report)'s stock price crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of GBX 1,032.66 ($13.99) and traded as high as GBX 1,079 ($14.62). Smith & Nephew shares last traded at GBX 1,074.50 ($14.56), with a volume of 3,177,114 shares changing hands.
Smith & Nephew Stock Up 0.2%
The company has a 50-day simple moving average of GBX 1,037.65 and a 200 day simple moving average of GBX 1,032.96. The company has a market cap of £11.80 billion, a P/E ratio of 38.76, a P/E/G ratio of 0.46 and a beta of 0.62. The company has a current ratio of 2.51, a quick ratio of 0.84 and a debt-to-equity ratio of 70.22.
Insider Transactions at Smith & Nephew
In related news, insider Sybella Stanley acquired 3,810 shares of the company's stock in a transaction that occurred on Wednesday, March 26th. The shares were bought at an average price of GBX 1,101 ($14.92) per share, with a total value of £41,948.10 ($56,847.95). Also, insider Jeremy (Jez) Maiden acquired 1,855 shares of the company's stock in a transaction that occurred on Thursday, May 1st. The shares were bought at an average cost of GBX 1,070 ($14.50) per share, for a total transaction of £19,848.50 ($26,898.63). Corporate insiders own 0.19% of the company's stock.
Smith & Nephew Company Profile
(
Get Free Report)
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.
Read More
Before you consider Smith & Nephew, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Smith & Nephew wasn't on the list.
While Smith & Nephew currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
